{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:01:05Z","timestamp":1794502865572,"version":"4.9.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41584-021-00694-z","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T11:59:26Z","timestamp":1633435166000},"page":"678-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-8232","authenticated-orcid":false,"given":"Fabrizio","family":"De Benedetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-136X","authenticated-orcid":false,"given":"Alexei A.","family":"Grom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"694_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","volume":"140","author":"DL Kastner","year":"2010","unstructured":"Kastner, D. L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784\u2013790 (2010).","journal-title":"Cell"},{"key":"694_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2018.09.014","volume":"55","author":"N Martinez-Quiles","year":"2018","unstructured":"Martinez-Quiles, N. & Goldbach-Mansky, R. Updates on autoinflammatory diseases. Curr. Opin. Immunol. 55, 97\u2013105 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"694_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/art.41285","volume":"72","author":"LA Henderson","year":"2020","unstructured":"Henderson, L. A. et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 72, 1059\u20131063 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"694_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41\u2013101 (2007).","journal-title":"Adv. Immunol."},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2567.2008.02905.x","volume":"126","author":"L Darwich","year":"2009","unstructured":"Darwich, L. et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 126, 386\u2013393 (2009).","journal-title":"Immunology"},{"key":"694_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.immuni.2012.09.007","volume":"37","author":"J Zhu","year":"2012","unstructured":"Zhu, J. et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37, 660\u2013673 (2012).","journal-title":"Immunity"},{"key":"694_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01978-14","volume":"5","author":"JE Suarez-Ramirez","year":"2014","unstructured":"Suarez-Ramirez, J. E., Tarrio, M. L., Kim, K., Demers, D. A. & Biron, C. A. CD8 T cells in innate immune responses: using STAT4-dependent but antigen-independent pathways to gamma interferon during viral infection. mBio 5, e01978-01914 (2014).","journal-title":"mBio"},{"key":"694_CR8","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2010-07-294702","volume":"117","author":"Y Kannan","year":"2011","unstructured":"Kannan, Y. et al. I\u03baB\u03b6 augments IL-12- and IL-18-mediated IFN-\u03b3 production in human NK cells. Blood 117, 2855\u20132863 (2011).","journal-title":"Blood"},{"key":"694_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","volume":"9","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi, K. Unique action of interleukin-18 on T cells and other immune cells. Front. Immunol. 9, 763 (2018).","journal-title":"Front. Immunol."},{"key":"694_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/icb.2012.9","volume":"90","author":"NA de Weerd","year":"2012","unstructured":"de Weerd, N. A. & Nguyen, T. The interferons and their receptors \u2014 distribution and regulation. Immunol. Cell Biol. 90, 483\u2013491 (2012).","journal-title":"Immunol. Cell Biol."},{"key":"694_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.imbio.2017.10.005","volume":"223","author":"DA Chistiakov","year":"2018","unstructured":"Chistiakov, D. A., Myasoedova, V. A., Revin, V. V., Orekhov, A. N. & Bobryshev, Y. V. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology 223, 101\u2013111 (2018).","journal-title":"Immunobiology"},{"key":"694_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).","journal-title":"F1000Prime Rep."},{"key":"694_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787\u2013795 (2012).","journal-title":"J. Clin. Invest."},{"key":"694_CR14","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.4049\/jimmunol.1302379","volume":"193","author":"C Wu","year":"2014","unstructured":"Wu, C. et al. IFN-\u03b3 primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. J. Immunol. 193, 3036\u20133044 (2014).","journal-title":"J. Immunol."},{"key":"694_CR15","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1128\/iai.61.7.2872-2878.1993","volume":"61","author":"M Asano","year":"1993","unstructured":"Asano, M., Nakane, A. & Minagawa, T. Endogenous gamma interferon is essential in granuloma formation induced by glycolipid-containing mycolic acid in mice. Infect. Immun. 61, 2872\u20132878 (1993).","journal-title":"Infect. Immun."},{"key":"694_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1189\/jlb.0412205","volume":"95","author":"J Jaczewska","year":"2014","unstructured":"Jaczewska, J. et al. TNF-\u03b1 and IFN-\u03b3 promote lymphocyte adhesion to endothelial junctional regions facilitating transendothelial migration. J. Leukoc. Biol. 95, 265\u2013274 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"694_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2017","unstructured":"Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front. Immunol. 8, 1970 (2017).","journal-title":"Front. Immunol."},{"key":"694_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/cimm.2001.1819","volume":"211","author":"JE Pearl","year":"2001","unstructured":"Pearl, J. E., Saunders, B., Ehlers, S., Orme, I. M. & Cooper, A. M. Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse. Cell Immunol. 211, 43\u201350 (2001).","journal-title":"Cell Immunol."},{"key":"694_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/imm.12524","volume":"146","author":"EJ Swindle","year":"2015","unstructured":"Swindle, E. J., Brown, J. M., R\u00e5dinger, M., DeLeo, F. R. & Metcalfe, D. D. Interferon-\u03b3 enhances both the anti-bacterial and the pro-inflammatory response of human mast cells to Staphylococcus aureus. Immunology 146, 470\u2013485 (2015).","journal-title":"Immunology"},{"key":"694_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.immuni.2012.10.010","volume":"37","author":"SK Lee","year":"2012","unstructured":"Lee, S. K. et al. Interferon-\u03b3 excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37, 880\u2013892 (2012).","journal-title":"Immunity"},{"key":"694_CR21","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1084\/jem.20180927","volume":"215","author":"D Fang","year":"2018","unstructured":"Fang, D. et al. Transient T-bet expression functionally specifies a distinct T follicular helper subset. J. Exp. Med. 215, 2705\u20132714 (2018).","journal-title":"J. Exp. Med."},{"key":"694_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1084\/jem.20151724","volume":"213","author":"SW Jackson","year":"2016","unstructured":"Jackson, S. W. et al. B cell IFN-\u03b3 receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J. Exp. Med. 213, 733\u2013750 (2016).","journal-title":"J. Exp. Med."},{"key":"694_CR23","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1073\/pnas.082114899","volume":"99","author":"SL Peng","year":"2002","unstructured":"Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl Acad. Sci. USA 99, 5545\u20135550 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"694_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. & Marsh, R. A. Pediatric hemophagocytic lymphohistiocytosis. Blood 135, 1332\u20131343 (2020).","journal-title":"Blood"},{"key":"694_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428194.2018.1482543","volume":"60","author":"NS Bhatt","year":"2019","unstructured":"Bhatt, N. S., Oshrine, B. & An Talano, J. Hemophagocytic lymphohistiocytosis in adults. Leuk. Lymphoma 60, 19\u201328 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"694_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter, J. I. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124\u2013131 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"694_CR27","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile, J. F. et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127, 2672\u20132681 (2016).","journal-title":"Blood"},{"key":"694_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259\u2013268 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"694_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-016-0130-4","volume":"15","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia, C., Prencipe, G. & De Benedetti, F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr. Rheumatol. Online J. 15, 5 (2017).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"694_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli, A. et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 75, 481\u2013489 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR31","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten, E. et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130, 2728\u20132738 (2017).","journal-title":"Blood"},{"key":"694_CR32","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","volume":"78","author":"JI Henter","year":"1991","unstructured":"Henter, J. I. et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78, 2918\u20132922 (1991).","journal-title":"Blood"},{"key":"694_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/(SICI)1096-911X(199809)31:3<131::AID-MPO1>3.0.CO;2-C","volume":"31","author":"S Imashuku","year":"1998","unstructured":"Imashuku, S. et al. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol. 31, 131\u2013137 (1998).","journal-title":"Med. Pediatr. Oncol."},{"key":"694_CR34","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2001-12-0260","volume":"100","author":"EM Schneider","year":"2002","unstructured":"Schneider, E. M. et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100, 2891\u20132898 (2002).","journal-title":"Blood"},{"key":"694_CR35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau, A. D., Roskams, T., Van Damme-Lombaerts, R., Matthys, P. & Wouters, C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 105, 1648\u20131651 (2005).","journal-title":"Blood"},{"key":"694_CR36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","volume":"160","author":"XJ Xu","year":"2012","unstructured":"Xu, X. J. et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J. Pediatr. 160, 984\u2013990.e1 (2012).","journal-title":"J. Pediatr."},{"key":"694_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226043","volume":"14","author":"G Prencipe","year":"2019","unstructured":"Prencipe, G. et al. The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. PLoS ONE 14, e0226043 (2019).","journal-title":"PLoS ONE"},{"key":"694_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","volume":"85","author":"SL Yang","year":"2016","unstructured":"Yang, S. L. et al. Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85, 14\u201317 (2016).","journal-title":"Cytokine"},{"key":"694_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trsl.2016.07.023","volume":"180","author":"V Buatois","year":"2017","unstructured":"Buatois, V. et al. Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl. Res. 180, 37\u201352.e2 (2017).","journal-title":"Transl. Res."},{"key":"694_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia, C. et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 76, 166\u2013172 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan, M. B., Hildeman, D., Kappler, J. & Marrack, P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104, 735\u2013743 (2004).","journal-title":"Blood"},{"key":"694_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","volume":"127","author":"JE Rood","year":"2016","unstructured":"Rood, J. E. et al. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood 127, 426\u2013435 (2016).","journal-title":"Blood"},{"key":"694_CR43","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2012-07-441139","volume":"121","author":"T K\u00f6gl","year":"2013","unstructured":"K\u00f6gl, T. et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 121, 604\u2013613 (2013).","journal-title":"Blood"},{"key":"694_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/emmm.200900009","volume":"1","author":"J Pachlopnik Schmid","year":"2009","unstructured":"Pachlopnik Schmid, J. et al. Neutralization of IFN\u03b3 defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol. Med. 1, 112\u2013124 (2009).","journal-title":"EMBO Mol. Med."},{"key":"694_CR45","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.20102538","volume":"208","author":"EE Zoller","year":"2011","unstructured":"Zoller, E. E. et al. Hemophagocytosis causes a consumptive anemia of inflammation. J. Exp. Med. 208, 1203\u20131214 (2011).","journal-title":"J. Exp. Med."},{"key":"694_CR46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.immuni.2006.09.010","volume":"25","author":"SL van Dommelen","year":"2006","unstructured":"van Dommelen, S. L. et al. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25, 835\u2013848 (2006).","journal-title":"Immunity"},{"key":"694_CR47","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.jaci.2018.10.068","volume":"143","author":"S Humblet-Baron","year":"2019","unstructured":"Humblet-Baron, S. et al. IFN-\u03b3 and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. J. Allergy Clin. Immunol. 143, 2215\u20132226.e7 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"694_CR48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/art.41076","volume":"72","author":"TN Burn","year":"2020","unstructured":"Burn, T. N. et al. Genetic deficiency of interferon-gamma reveals interferon-gamma-independent manifestations of murine hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72, 335\u2013347 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"694_CR49","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jaci.2014.11.030","volume":"135","author":"B Tesi","year":"2015","unstructured":"Tesi, B. et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency. J. Allergy Clin. Immunol. 135, 1638\u20131641 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"694_CR50","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens, E. M. et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. 121, 2264\u20132277 (2011).","journal-title":"J. Clin. Invest."},{"key":"694_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/art.40683","volume":"71","author":"LK Weaver","year":"2019","unstructured":"Weaver, L. K., Chu, N. & Behrens, E. M. Brief report: interferon-\u03b3-mediated immunopathology potentiated by toll-like receptor 9 activation in a murine model of macrophage activation syndrome. Arthritis Rheumatol. 71, 161\u2013168 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"694_CR52","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.4049\/jimmunol.1501035","volume":"196","author":"E Brisse","year":"2016","unstructured":"Brisse, E. et al. Mouse cytomegalovirus infection in BALB\/c mice resembles virus-associated secondary hemophagocytic lymphohistiocytosis and shows a pathogenesis distinct from primary hemophagocytic lymphohistiocytosis. J. Immunol. 196, 3124\u20133134 (2016).","journal-title":"J. Immunol."},{"key":"694_CR53","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12985-017-0908-0","volume":"14","author":"E Brisse","year":"2017","unstructured":"Brisse, E. et al. Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis. Virol. J. 14, 240 (2017).","journal-title":"Virol. J."},{"key":"694_CR54","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F de Benedetti","year":"1991","unstructured":"de Benedetti, F. et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34, 1158\u20131163 (1991).","journal-title":"Arthritis Rheum."},{"key":"694_CR55","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385\u20132395 (2012).","journal-title":"N. Engl. J. Med."},{"key":"694_CR56","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/art.33496","volume":"64","author":"R Strippoli","year":"2012","unstructured":"Strippoli, R. et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 64, 1680\u20131688 (2012).","journal-title":"Arthritis Rheum."},{"key":"694_CR57","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","volume":"141","author":"G Prencipe","year":"2018","unstructured":"Prencipe, G. et al. Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J. Allergy Clin. Immunol. 141, 1439\u20131449 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"694_CR58","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss, E. S. et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 131, 1442\u20131455 (2018).","journal-title":"Blood"},{"key":"694_CR59","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin, S. et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology 59, 361\u2013366 (2020).","journal-title":"Rheumatology"},{"key":"694_CR60","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","volume":"131","author":"C Girard-Guyonvarc\u2019h","year":"2018","unstructured":"Girard-Guyonvarc\u2019h, C. et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood 131, 1430\u20131441 (2018).","journal-title":"Blood"},{"key":"694_CR61","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood.2019003846","volume":"136","author":"P Tsoukas","year":"2020","unstructured":"Tsoukas, P. et al. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation. Blood 136, 2162\u20132174 (2020).","journal-title":"Blood"},{"key":"694_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12969-020-00444-7","volume":"18","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. et al. Proceedings from the 2nd next gen therapies for systemic juvenile idiopathic arthritis and macrophage activation syndrome symposium held on October 3\u20134, 2019. Pediatr. Rheumatol. Online J. 18, 53 (2020).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"694_CR63","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert, G. S. et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 71, 1943\u20131954 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"694_CR64","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper, V. E. et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann. Rheum. Dis. 78, 1722\u20131731 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR65","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2014-05-575225","volume":"125","author":"S Iriguchi","year":"2015","unstructured":"Iriguchi, S. et al. T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung. Blood 125, 370\u2013382 (2015).","journal-title":"Blood"},{"key":"694_CR66","doi-asserted-by":"publisher","first-page":"147593","DOI":"10.1172\/jci.insight.147593","volume":"6","author":"DK Gao","year":"2021","unstructured":"Gao, D. K. et al. IFN-\u03b3 is essential for alveolar macrophage driven pulmonary inflammation in macrophage activation syndrome. JCI Insight 6, 147593 (2021).","journal-title":"JCI Insight"},{"key":"694_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"694_CR68","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154\u20135157 (2013).","journal-title":"Blood"},{"key":"694_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.28","volume":"3","author":"JL Brady","year":"2014","unstructured":"Brady, J. L. et al. Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin. Transl. Immunol. 3, e29 (2014).","journal-title":"Clin. Transl. Immunol."},{"key":"694_CR70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/imr.12768","volume":"290","author":"JH Oved","year":"2019","unstructured":"Oved, J. H., Barrett, D. M. & Teachey, D. T. Cellular therapy: immune-related complications. Immunol. Rev. 290, 114\u2013126 (2019).","journal-title":"Immunol. Rev."},{"key":"694_CR71","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"694_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1546-0096-12-33","volume":"12","author":"CH Wouters","year":"2014","unstructured":"Wouters, C. H., Maes, A., Foley, K. P., Bertin, J. & Rose, C. D. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr. Rheumatol. Online J. 12, 33 (2014).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"694_CR73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaci.2017.04.013","volume":"141","author":"S Takada","year":"2018","unstructured":"Takada, S. et al. Pluripotent stem cell models of Blau syndrome reveal an IFN-\u03b3-dependent inflammatory response in macrophages. J. Allergy Clin. Immunol. 141, 339\u2013349.e11 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"694_CR74","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1167\/iovs.08-2756","volume":"50","author":"HL Rosenzweig","year":"2009","unstructured":"Rosenzweig, H. L. et al. Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. Invest. Ophthalmol. Vis. Sci. 50, 1739\u20131745 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"694_CR75","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jaci.2012.02.004","volume":"129","author":"CE Janssen","year":"2012","unstructured":"Janssen, C. E. et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J. Allergy Clin. Immunol. 129, 1076\u20131084 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"694_CR76","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ajo.2017.08.017","volume":"187","author":"IL Sarens","year":"2018","unstructured":"Sarens, I. L. et al. Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am. J. Ophthalmol. 187, 158\u2013166 (2018).","journal-title":"Am. J. Ophthalmol."},{"key":"694_CR77","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.4049\/jimmunol.162.12.7241","volume":"162","author":"JP Seery","year":"1999","unstructured":"Seery, J. P. et al. A central role for alpha beta T cells in the pathogenesis of murine lupus. J. Immunol. 162, 7241\u20137248 (1999).","journal-title":"J. Immunol."},{"key":"694_CR78","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/03009740500417791","volume":"35","author":"P Enghard","year":"2006","unstructured":"Enghard, P., Langnickel, D. & Riemekasten, G. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB\/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand. J. Rheumatol. 35, 209\u2013216 (2006).","journal-title":"Scand. J. Rheumatol."},{"key":"694_CR79","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1084\/jem.166.3.798","volume":"166","author":"CO Jacob","year":"1987","unstructured":"Jacob, C. O., van der Meide, P. H. & McDevitt, H. O. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166, 798\u2013803 (1987).","journal-title":"J. Exp. Med."},{"key":"694_CR80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/eji.1830250103","volume":"25","author":"L Ozmen","year":"1995","unstructured":"Ozmen, L. et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB\/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25, 6\u201312 (1995).","journal-title":"Eur. J. Immunol."},{"key":"694_CR81","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.4049\/jimmunol.160.8.3713","volume":"160","author":"C Haas","year":"1998","unstructured":"Haas, C. & Ryffel, B. & Le Hir, M. IFN-\u03b3 receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB \u00d7 NZW)F1 mice. J. Immunol. 160, 3713\u20133718 (1998).","journal-title":"J. Immunol."},{"key":"694_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1172\/JCI750","volume":"101","author":"D Balomenos","year":"1998","unstructured":"Balomenos, D., Rumold, R. & Theofilopoulos, A. N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101, 364\u2013371 (1998).","journal-title":"J. Clin. Invest."},{"key":"694_CR83","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20151722","volume":"213","author":"PP Domeier","year":"2016","unstructured":"Domeier, P. P. et al. IFN-\u03b3 receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J. Exp. Med. 213, 715\u2013732 (2016).","journal-title":"J. Exp. Med."},{"key":"694_CR84","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1177\/0961203312451200","volume":"21","author":"A Rana","year":"2012","unstructured":"Rana, A. et al. Gene expression of cytokines (TNF-\u03b1, IFN-\u03b3), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 21, 1105\u20131112 (2012).","journal-title":"Lupus"},{"key":"694_CR85","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.molimm.2014.05.001","volume":"61","author":"BD Lyn-Cook","year":"2014","unstructured":"Lyn-Cook, B. D. et al. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 61, 38\u201343 (2014).","journal-title":"Mol. Immunol."},{"key":"694_CR86","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0961203315605367","volume":"25","author":"V Kokic","year":"2016","unstructured":"Kokic, V. et al. Relationship between vitamin D, IFN-\u03b3, and E2 levels in systemic lupus erythematosus. Lupus 25, 282\u2013288 (2016).","journal-title":"Lupus"},{"key":"694_CR87","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","volume":"75","author":"ME Munroe","year":"2016","unstructured":"Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014\u20132021 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR88","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/art.37909","volume":"65","author":"L Chiche","year":"2013","unstructured":"Chiche, L., Jourde-Chiche, N., Pascual, V. & Chaussabel, D. Current perspectives on systems immunology approaches to rheumatic diseases. Arthritis Rheum. 65, 1407\u20131417 (2013).","journal-title":"Arthritis Rheum."},{"key":"694_CR89","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/mt.2008.88","volume":"16","author":"J Zhu","year":"2008","unstructured":"Zhu, J., Huang, X. & Yang, Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16, 1300\u20131307 (2008).","journal-title":"Mol. Ther."},{"key":"694_CR90","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138345","volume":"5","author":"A Fava","year":"2020","unstructured":"Fava, A. et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-\u03b3 response gradient in lupus nephritis. JCI Insight 5, e138345 (2020).","journal-title":"JCI Insight"},{"key":"694_CR91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"694_CR92","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208\u2013e219 (2019).","journal-title":"Lancet Rheumatol."},{"key":"694_CR93","doi-asserted-by":"publisher","first-page":"16139","DOI":"10.1074\/jbc.271.27.16139","volume":"271","author":"H Lortat-Jacob","year":"1996","unstructured":"Lortat-Jacob, H., Baltzer, F. & Grimaud, J. A. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J. Biol. Chem. 271, 16139\u201316143 (1996).","journal-title":"J. Biol. Chem."},{"key":"694_CR94","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/jir.1988.8.573","volume":"8","author":"I Rutenfranz","year":"1988","unstructured":"Rutenfranz, I. & Kirchner, H. Pharmacokinetics of recombinant murine interferon-gamma in mice. J. Interferon Res. 8, 573\u2013580 (1988).","journal-title":"J. Interferon Res."},{"key":"694_CR95","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fimmu.2021.663329","volume":"12","author":"A Pascarella","year":"2021","unstructured":"Pascarella, A. et al. Monocytes from patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis are hyperresponsive to interferon gamma. Front. Immunol. 12, 801 (2021).","journal-title":"Front. Immunol."},{"key":"694_CR96","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.4049\/jimmunol.170.9.4833","volume":"170","author":"X Hu","year":"2003","unstructured":"Hu, X., Li, W. P., Meng, C. & Ivashkiv, L. B. Inhibition of IFN-\u03b3 signaling by glucocorticoids. J. Immunol. 170, 4833\u20134839 (2003).","journal-title":"J. Immunol."},{"key":"694_CR97","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/CVI.00306-10","volume":"18","author":"MF Ibarra","year":"2011","unstructured":"Ibarra, M. F. et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin. Vaccin. Immunol. 18, 609\u2013614 (2011).","journal-title":"Clin. Vaccin. Immunol."},{"key":"694_CR98","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/pbc.24480","volume":"60","author":"T Wada","year":"2013","unstructured":"Wada, T. et al. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr. Blood Cancer 60, E46\u2013E48 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"694_CR99","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu, M. et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 49, 1645\u20131653 (2010).","journal-title":"Rheumatology"},{"key":"694_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa299","author":"M Mizuta","year":"2020","unstructured":"Mizuta, M. et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keaa299 (2020).","journal-title":"Rheumatology"},{"key":"694_CR101","unstructured":"de Matteis, A. et al. Traditional laboratory parameters and new biomarkers in macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 72 (suppl 4). https:\/\/acrabstracts.org\/abstract\/traditional-laboratory-parameters-and-new-biomarkers-in-macrophage-activation-syndrome-and-secondary-hemophagocytic-lymphohistiocytosis\/ (2020)."},{"key":"694_CR102","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/ard.52.6.429","volume":"52","author":"KL Lim","year":"1993","unstructured":"Lim, K. L., Jones, A. C., Brown, N. S. & Powell, R. J. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann. Rheum. Dis. 52, 429\u2013435 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR103","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/jbmr.3532","volume":"33","author":"MP Whyte","year":"2018","unstructured":"Whyte, M. P. et al. Unique variant of NOD2 pediatric granulomatous arthritis with severe 1,25-dihydroxyvitamin D-mediated hypercalcemia and generalized osteosclerosis. J. Bone Min. Res. 33, 2071\u20132080 (2018).","journal-title":"J. Bone Min. Res."},{"key":"694_CR104","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207\u2013215 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"694_CR105","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","volume":"119","author":"M Mizuta","year":"2019","unstructured":"Mizuta, M., Shimizu, M., Inoue, N., Nakagishi, Y. & Yachie, A. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. Cytokine 119, 182\u2013187 (2019).","journal-title":"Cytokine"},{"key":"694_CR106","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2141.2009.07957.x","volume":"148","author":"LT My","year":"2010","unstructured":"My, L. T. et al. Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children. Br. J. Haematol. 148, 301\u2013310 (2010).","journal-title":"Br. J. Haematol."},{"key":"694_CR107","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1046\/j.1365-2249.2003.02237.x","volume":"133","author":"H Takada","year":"2003","unstructured":"Takada, H. et al. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin. Exp. Immunol. 133, 448\u2013453 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"694_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/srep46652","volume":"7","author":"JH Han","year":"2017","unstructured":"Han, J. H. et al. Elevated circulating levels of the interferon-\u03b3-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still\u2019s disease. Sci. Rep. 7, 46652 (2017).","journal-title":"Sci. Rep."},{"key":"694_CR109","doi-asserted-by":"publisher","first-page":"108252","DOI":"10.1016\/j.clim.2019.108252","volume":"208","author":"M Takakura","year":"2019","unstructured":"Takakura, M. et al. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Clin. Immunol. 208, 108252 (2019).","journal-title":"Clin. Immunol."},{"key":"694_CR110","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/annrheumdis-2020-217470","volume":"80","author":"GS Schulert","year":"2021","unstructured":"Schulert, G. S. et al. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3 hyper-responsiveness and risk for macrophage activation syndrome. Ann. Rheum. Dis. 80, 617\u2013625 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR111","doi-asserted-by":"publisher","first-page":"934161","DOI":"10.1155\/2012\/934161","volume":"2012","author":"T Carvalheiro","year":"2012","unstructured":"Carvalheiro, T. et al. Tolerogenic versus inflammatory activity of peripheral blood monocytes and dendritic cells subpopulations in systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 934161 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"694_CR112","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0961203310364400","volume":"19","author":"GA Ferreira","year":"2010","unstructured":"Ferreira, G. A., Teixeira, A. L. & Sato, E. I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19, 927\u2013934 (2010).","journal-title":"Lupus"},{"key":"694_CR113","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli, F. et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 382, 1811\u20131822 (2020).","journal-title":"N. Engl. J. Med."},{"key":"694_CR114","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","volume":"3","author":"DT Lounder","year":"2019","unstructured":"Lounder, D. T., Bin, Q., de Min, C. & Jordan, M. B. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 3, 47\u201350 (2019).","journal-title":"Blood Adv."},{"issue":"Suppl 1","key":"694_CR115","volume":"67","author":"C Bracaglia","year":"2019","unstructured":"Bracaglia, C. et al. IFNg neutralization in patients with NRLC4- and CDC42-associated autoinflammatory disease characterized by recurrent and severe HLH. Pediatr. Blood Cancer 67 (Suppl 1), e28077 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"694_CR116","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1084\/jem.20190147","volume":"216","author":"MT Lam","year":"2019","unstructured":"Lam, M. T. et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J. Exp. Med. 216, 2778\u20132799 (2019).","journal-title":"J. Exp. Med."},{"key":"694_CR117","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/annrheumdis-2020-eular.3169","volume":"79","author":"F De Benedetti","year":"2020","unstructured":"De Benedetti, F. et al. Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann. Rheum. Dis. 79, 180 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"694_CR118","doi-asserted-by":"publisher","first-page":"887","DOI":"10.21037\/atm-20-3127","volume":"8","author":"JB Gabr","year":"2020","unstructured":"Gabr, J. B. et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still\u2019s disease: case report and review of the literature. Ann. Transl. Med. 8, 887 (2020).","journal-title":"Ann. Transl. Med."},{"key":"694_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000226","volume":"4","author":"MJ Boedigheimer","year":"2017","unstructured":"Boedigheimer, M. J. et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-\u03b3 monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci. Med. 4, e000226 (2017).","journal-title":"Lupus Sci. Med."},{"key":"694_CR120","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s11095-014-1492-2","volume":"32","author":"P Chen","year":"2015","unstructured":"Chen, P. et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm. Res. 32, 640\u2013653 (2015).","journal-title":"Pharm. Res."},{"key":"694_CR121","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1182\/blood-2006-03-009266","volume":"108","author":"S Bozza","year":"2006","unstructured":"Bozza, S. et al. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108, 3387\u20133396 (2006).","journal-title":"Blood"},{"key":"694_CR122","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.188.3.577","volume":"188","author":"RM Presti","year":"1998","unstructured":"Presti, R. M., Pollock, J. L., Dal Canto, A. J., O\u2019Guin, A. K. & Virgin, H. W. T. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188, 577\u2013588 (1998).","journal-title":"J. Exp. Med."},{"key":"694_CR123","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-2567.2000.00955.x","volume":"99","author":"S Bao","year":"2000","unstructured":"Bao, S., Beagley, K. W., France, M. P., Shen, J. & Husband, A. J. Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection. Immunology 99, 464\u2013472 (2000).","journal-title":"Immunology"},{"key":"694_CR124","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cimid.2007.07.014","volume":"31","author":"I Fidan","year":"2008","unstructured":"Fidan, I., Yesilyurt, E., Gurelik, F. C., Erdal, B. & Imir, T. Effects of recombinant interferon-gamma on cytokine secretion from monocyte-derived macrophages infected with Salmonella typhi. Comp. Immunol. Microbiol. Infect. Dis. 31, 467\u2013475 (2008).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"694_CR125","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1128\/AAC.01506-07","volume":"52","author":"J Salat","year":"2008","unstructured":"Salat, J., Jelinek, J., Chmelar, J. & Kopecky, J. Efficacy of gamma interferon and specific antibody for treatment of microsporidiosis caused by Encephalitozoon cuniculi in SCID mice. Antimicrob. Agents Chemother. 52, 2169\u20132174 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"694_CR126","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/icb.2009.41","volume":"87","author":"N Sumaria","year":"2009","unstructured":"Sumaria, N. et al. The roles of interferon-gamma and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity. Immunol. Cell Biol. 87, 559\u2013566 (2009).","journal-title":"Immunol. Cell Biol."},{"key":"694_CR127","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0022-3476(99)70064-8","volume":"135","author":"SE Dorman","year":"1999","unstructured":"Dorman, S. E. et al. Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 135, 640\u2013643 (1999).","journal-title":"J. Pediatr."},{"key":"694_CR128","first-page":"418","volume":"26","author":"DQ Tran","year":"2005","unstructured":"Tran, D. Q. Susceptibility to mycobacterial infections due to interferon-gamma and interleukin-12 pathway defects. Allergy Asthma Proc. 26, 418\u2013421 (2005).","journal-title":"Allergy Asthma Proc."},{"key":"694_CR129","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI19316","volume":"115","author":"B Kampmann","year":"2005","unstructured":"Kampmann, B. et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J. Clin. Invest. 115, 2480\u20132488 (2005).","journal-title":"J. Clin. Invest."},{"key":"694_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076371","volume":"8","author":"P Wongkulab","year":"2013","unstructured":"Wongkulab, P., Wipasa, J., Chaiwarith, R. & Supparatpinyo, K. Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand. PLoS ONE 8, e76371 (2013).","journal-title":"PLoS ONE"},{"key":"694_CR131","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/hmg\/ddr029","volume":"20","author":"I Sologuren","year":"2011","unstructured":"Sologuren, I. et al. Partial recessive IFN-\u03b3R1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum. Mol. Genet. 20, 1509\u20131523 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"694_CR132","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1046\/j.1365-2249.2000.01284.x","volume":"121","author":"DA Lammas","year":"2000","unstructured":"Lammas, D. A., Casanova, J. L. & Kumararatne, D. S. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin. Exp. Immunol. 121, 417\u2013425 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"694_CR133","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1086\/380453","volume":"38","author":"R Doffinger","year":"2004","unstructured":"Doffinger, R. et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10\u2013e14 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"694_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-24","volume":"13","author":"S Poulin","year":"2013","unstructured":"Poulin, S. et al. Fatal Mycobacterium colombiense\/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. BMC Infect. Dis. 13, 24 (2013).","journal-title":"BMC Infect. Dis."},{"key":"694_CR135","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/gut.2005.079392","volume":"55","author":"DW Hommes","year":"2006","unstructured":"Hommes, D. W. et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn\u2019s disease. Gut 55, 1131\u20131137 (2006).","journal-title":"Gut"},{"key":"694_CR136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ibd.21038","volume":"16","author":"W Reinisch","year":"2010","unstructured":"Reinisch, W. et al. Fontolizumab in moderate to severe Crohn\u2019s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233\u2013242 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"694_CR137","unstructured":"US Food and Drug Administration. Center for Drug Evaluation Research. BLA Multi-Disciplinary Review and Evaluation. BLA 761107. GAMIFANT(emapalumab), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761107Orig1s000MultidisciplineR.pdf (2018)."},{"key":"694_CR138","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3324\/haematol.2020.255620","volume":"106","author":"F Tucci","year":"2021","unstructured":"Tucci, F. et al. Treatment with emapalumab in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated BCGitis. Haematologica 106, 641\u2013646 (2021).","journal-title":"Haematologica"},{"key":"694_CR139","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/art.39933","volume":"69","author":"K Put","year":"2017","unstructured":"Put, K. et al. Inflammatory gene expression profile and defective interferon-gamma and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients. Arthritis Rheumatol. 69, 213\u2013224 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"694_CR140","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gut.2005.079434","volume":"55","author":"W Reinisch","year":"2006","unstructured":"Reinisch, W. et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon \u03b3 antibody, in patients with moderate to severe Crohn\u2019s disease. Gut 55, 1138\u20131144 (2006).","journal-title":"Gut"},{"key":"694_CR141","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/art.40052","volume":"69","author":"VP Werth","year":"2017","unstructured":"Werth, V. P. et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 69, 1028\u20131034 (2017).","journal-title":"Arthritis Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00694-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00694-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00694-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T22:54:55Z","timestamp":1673391295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00694-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":141,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00694-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"31 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.D.B. has received research grants from AbbVie, Novartis, Pfizer, Roche, Sanofi, Novimmune and Sobi. A.A.G. has served as a consultant for Sobi, AB2Bio, Juno and Novartis, and has received research support from Novartis, Sobi and AB2Bio. G.P., C.B. and E.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}